Sunday, November 13, 2016
- 9:00AM-11:00AM
-
Abstract Number: 123
A Panel of Urinary Biomarkers to Assess Renal Involvement in Latin American Patients with Systemic Lupus Erythematosus
Healthcare Disparities in Rheumatology - Poster I- 9:00AM-11:00AM
-
Abstract Number: 823
A Phase 2 Study of Pomalidomide (CC-4047) to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Effectiveness in Subjects with Systemic Sclerosis with Interstitial Lung Disease
Systemic Sclerosis, Fibrosing Syndromes, and Raynaud's – Clinical Aspects and Therapeutics - Poster I- 9:00AM-11:00AM
-
Abstract Number: 198
A Phase 2 Study to Evaluate the Efficacy and Safety of Febuxostat Extended- Versus Immediate-Release Formulations in Patients with Gout and Moderate Renal Impairment
Metabolic and Crystal Arthropathies - Poster I: Clinical Practice- 9:00AM-11:00AM
-
Abstract Number: 199
A Phase 3 Study to Evaluate the Efficacy and Safety of Febuxostat Extended- Versus Immediate-Release Formulations in Patients with Gout
Metabolic and Crystal Arthropathies - Poster I: Clinical Practice- 9:00AM-11:00AM
-
Abstract Number: 748
A Phase 4, Multicenter, Randomized, Open-Label Study to Evaluate the Effect of Belimumab on Vaccine Responses in Patients with Systemic Lupus Erythematosus
Systemic Lupus Erythematosus – Clinical Aspects and Treatment - Poster I: Clinical Trial Design and Current Therapies- 9:00AM-11:00AM
-
Abstract Number: 742
A Pivotal Phase III, Randomized, Placebo-Controlled Study of Belimumab in Patients with Systemic Lupus Erythematosus Located in China, Japan, and South Korea
Systemic Lupus Erythematosus – Clinical Aspects and Treatment - Poster I: Clinical Trial Design and Current Therapies- 9:00AM-11:00AM
-
Abstract Number: 324
A Placebo Controlled Trial of Vertebral Fill Technique Vertebroplasty for Acute Painful Osteoporotic Fracture (VAPOUR Trial)
Osteoporosis and Metabolic Bone Disease – Clinical Aspects and Pathogenesis - Poster- 9:00AM-11:00AM
-
Abstract Number: 430
A Process to Obtain Hepatitis B Serology Screening on Immunocompromised Pediatric Rheumatology Patients
Quality Measures and Quality of Care - Poster I- 9:00AM-11:00AM
-
Abstract Number: 83
A Qualitative Study Exploring Participants’ Perception of the Making It Work Program, an Online Program to Help People with Inflammatory Arthritis Maintain Employment
Health Services Research - Poster I- 9:00AM-11:00AM
-
Abstract Number: 606
A Randomized, Double Blind, Single Dose Study to Assess the Pharmacokinetics, Safety, and Tolerability of ONS-3010 (Adalimumab, Oncobiologics, Inc.) Compared to Two Reference Products of Humira® (AbbVie) in Healthy Adult Subjects
Rheumatoid Arthritis – Small Molecules, Biologics and Gene Therapy - Poster I- 9:00AM-11:00AM
-
Abstract Number: 638
A Randomized, Open-Label, Single-Dose, Parallel-Group Trial to Determine the Pharmacokinetics, Safety and Immunogenicity of GP2017, a Proposed Adalimumab Biosimilar, Following a Single Subcutaneous Injection By an Autoinjector or Prefilled Syringe in Healthy Male Subjects
Rheumatoid Arthritis – Small Molecules, Biologics and Gene Therapy - Poster I- 9:00AM-11:00AM
-
Abstract Number: 71
A Rare Coding Allele in IFIH1 is Protective for Psoriatic Arthritis
Genetics, Genomics and Proteomics - Poster I- 9:00AM-11:00AM
-
Abstract Number: 27
A Rheumatologist’s Assessment of Therapy Responses (Rxresp) and Rheumatoid Factor Status (neg/pos) in 1995 Predicted Mortality through 2015 in a Community-Based Cohort of Incident Rheumatoid Arthritis Cases and Matched Control Subjects
Epidemiology and Public Health - Poster I